American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer
Background: Venous thromboembolism (VTE) is a common complication among patients
with cancer. Patients with cancer and VTE are at a markedly increased risk for morbidity and …
with cancer. Patients with cancer and VTE are at a markedly increased risk for morbidity and …
2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS) The …
SV Konstantinides, G Meyer, C Becattini… - European heart …, 2020 - academic.oup.com
determination and the implementation of preventive, diagnostic or therapeutic medical
strategies. However, the ESC Guidelines do not override in any way whatsoever the …
strategies. However, the ESC Guidelines do not override in any way whatsoever the …
Editor's Choice–European Society for Vascular Surgery (ESVS) 2021 clinical practice guidelines on the management of venous thrombosis
SK Kakkos, M Gohel, N Baekgaard… - European Journal of …, 2021 - ejves.com
2.1. 1. Epidemiology and burden of the disease. The annual incidence of first episode of
symptomatic DVT in the adult population ranges from 50 to 100 per 100 000 population, with …
symptomatic DVT in the adult population ranges from 50 to 100 per 100 000 population, with …
Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update
NS Key, AA Khorana, NM Kuderer, K Bohlke… - Journal of Clinical …, 2020 - ascopubs.org
PURPOSE To provide updated recommendations about prophylaxis and treatment of
venous thromboembolism (VTE) in patients with cancer. METHODS PubMed and the …
venous thromboembolism (VTE) in patients with cancer. METHODS PubMed and the …
The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation
J Steffel, P Verhamme, TS Potpara… - European heart …, 2018 - academic.oup.com
The current manuscript is the second update of the original Practical Guide, published in
2013 [Heidbuchel et al. European Heart Rhythm Association Practical Guide on the use of …
2013 [Heidbuchel et al. European Heart Rhythm Association Practical Guide on the use of …
Cancer-associated venous thromboembolism: burden, mechanisms, and management
Venous thromboembolism (VTE) is a significant health problem in the general population
but especially in cancer patients. In this review, we discuss the epidemiology and burden of …
but especially in cancer patients. In this review, we discuss the epidemiology and burden of …
[HTML][HTML] Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for treatment of cancer associated thrombosis (CAT): a systematic review and …
Introduction It is unclear if direct oral anticoagulants (DOACs) are effective and safe
alternatives to low-molecular-weight heparin (LMWHs) for the treatment of cancer …
alternatives to low-molecular-weight heparin (LMWHs) for the treatment of cancer …
International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with …
D Farge, H Bounameaux, B Brenner… - The Lancet …, 2016 - thelancet.com
Venous thromboembolism (VTE) is the second leading cause of death in patients with
cancer. These patients are at an increased risk of developing VTE and are more likely to …
cancer. These patients are at an increased risk of developing VTE and are more likely to …
Apixaban versus dalteparin for the treatment of acute venous thromboembolism in patients with cancer: the Caravaggio study
G Agnelli, C Becattini, R Bauersachs… - Thrombosis and …, 2018 - thieme-connect.com
International and national guidelines recommend low-molecular-weight heparin for the
treatment of venous thromboembolism (VTE) in patients with cancer. The aim of the …
treatment of venous thromboembolism (VTE) in patients with cancer. The aim of the …